GH:NASDAQ
Guardant Health Inc
$157.88
arrow_downward
-0.45%(-0.72) 1D
$157.88
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 19, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GH...
Open
$160.65
High
$163.91
Low
$155.00
Mkt. cap
21.19B
Avg. vol.
1.82M
Volume
1.87M
52-wk high
$191.01
52-wk low
$65.96
EPS
-$3.50
Beta
1.58
Shares outstanding
134.20M
No. of employees
2K
Open
$160.65
High
$163.91
Low
$155.00
Mkt. cap
21.19B
Avg. vol.
1.82M
Volume
1.87M
52-wk high
$191.01
52-wk low
$65.96
EPS
-$3.50
Beta
1.58
Shares outstanding
134.20M
No. of employees
2K
News stories
From web sources and news partners
Investing.com Nigeria
·
1 hour ago
Guardant Health director Tariq Musa sells $19,242 in stock By Investing.com
The Business Journals
·
7 hours ago
TwinStrand, UW notch another legal victory in patent dispute with Guardant Health
Stocks Down Under
·
10 hours ago
Guardant Health (NDQ:GH): The Company Betting Its Cancer Screening Method Will Be Revolutionary!
Seeking Alpha
·
15 hours ago
Guardant Health: Growth Remains Too Expensive, Reiterate Hold (NASDAQ:GH)
Profile
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia
About Guardant Health Inc
CEOHelmy Eltoukhy | AmirAli Talasaz
Employees2.5K
Founded2012
HeadquartersPalo Alto, California, United States
SectorHealth care provider
Websiteguardanthealth.com
Analyst ratings
Based on 19 analysts giving stock ratings to GH in the past 3 months
Strong buy
Buy
19
Hold
0
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for GH in the last 3 months.
Highest
Current $157.88
$225.00 (+42.51%)
Average
$203.29 (+28.76%)
Lowest
$180.00 (+14.01%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Eve Burstein Bernstein | Buy | Reiterated | $210.00 | +33% | 10/19/2026 |
Casey Woodring J.P. Morgan | Buy | Maintained | $195.00 | +23.5% | 10/14/2026 |
Kallum Titchmarsh Morgan Stanley | Buy | Reiterated | $200.00 | +26.7% | 10/13/2026 |
Lu Li Bank of America Securities | Buy | Maintained | $200.00 | +26.7% | 10/09/2026 |
Michael Ryskin Bank of America Securities | Buy | Maintained | $200.00 | +26.7% | 10/09/2026 |
Luke Sergott Barclays | Buy | Maintained | $220.00 | +39.3% | 10/07/2026 |
Subbu Nambi Guggenheim | Buy | Maintained | $200.00 | +26.7% | 10/01/2026 |
Evie Koslosky Goldman Sachs | Buy | Maintained | $225.00 | +42.5% | 09/20/2026 |
William Bonello Craig-Hallum | Buy | Maintained | - | - | 09/15/2026 |
David Westenberg Piper Sandler | Buy | Maintained | $193.00 | +22.2% | 09/15/2026 |
Unknown Analyst UBS | Buy | Maintained | $225.00 | +42.5% | 09/09/2026 |
Doug Schenkel UBS | Buy | Maintained | $225.00 | +42.5% | 09/09/2026 |
Jamie Clark Rothschild & Co Redburn | Buy | Initiated | $203.00 | +28.6% | 09/08/2026 |
Matt Larew William Blair | Buy | Maintained | - | - | 09/08/2026 |
Mark Massaro BTIG | Buy | Reiterated | $195.00 | +23.5% | 09/01/2026 |
Bradley Bowers Mizuho Securities | Buy | Maintained | $200.00 | +26.7% | 08/04/2026 |
Mason Carrico Stephens | Buy | Maintained | $195.00 | +23.5% | 08/04/2026 |
Kyle Mikson CFA Canaccord Genuity | Buy | Maintained | $205.00 | +29.8% | 08/02/2026 |
Daniel Arias Stifel Nicolaus | Buy | Maintained | $180.00 | +14% | 08/03/2026 |
Dan Leonard RBC Capital | Buy | Reiterated | $200.00 | +26.7% | 07/31/2026 |
Daniel Brennan TD Cowen | Buy | Reiterated | $210.00 | +33% | 07/31/2026 |
Brandon Couillard Wells Fargo | Buy | Maintained | $125.00 | -20.8% | 07/29/2026 |
Patrick B Donnelly Citi | Buy | Maintained | $215.00 | +36.2% | 07/08/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $200.00 | +26.7% | 07/06/2026 |
Puneet Souda Leerink Partners | Buy | Reiterated | - | - | 06/02/2026 |
Paige Chamberlain Wolfe Research | Buy | Reiterated | $150.00 | -5% | 06/01/2026 |
Unknown Analyst Wolfe Research | Buy | Reiterated | $150.00 | -5% | 06/01/2026 |
Andrew Brackmann William Blair | Buy | Maintained | - | - | 05/27/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $129.00 | -18.3% | 05/08/2026 |
Andrew Cooper Raymond James | Buy | Reiterated | $129.00 | -18.3% | 02/23/2026 |
Last report
Jul 30, 2026
Fiscal period
Q2 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.42 / -$0.39
-7.81%miss
arrow_downward
Revenue / Est. (USD)
334.98M / 314.43M
+6.53%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 265.20M | 281.27M | 301.66M | 334.98M |
Cost of goods sold | 93.59M | 99.49M | 104.92M | 115.95M |
Cost of revenue | 93.59M | 99.49M | 104.92M | 115.95M |
Research and development expenses | 89.96M | 98.26M | 91.04M | 96.53M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 180.53M | 204.20M | 227.06M | 250.61M |
Operating expense | 270.48M | 302.46M | 318.10M | 347.15M |
Total operating expenses | 364.07M | 401.96M | 423.02M | 463.10M |
Operating income | -98.87M | -120.69M | -121.35M | -128.12M |
Other non operating income | -48.00K | -4.69M | 1.55M | 308.00K |
EBT including unusual items | -92.59M | -130.22M | -111.70M | -119.96M |
EBT excluding unusual items | -92.47M | -116.52M | -111.70M | -118.96M |
Income tax expense | 136.00K | -1.73M | 372.00K | 185.00K |
Effective tax rate | -0.15% | 1.33% | -0.33% | -0.15% |
Other operating expenses | - | - | - | - |
Net income | -92.72M | -128.49M | -112.08M | -120.14M |
Net profit margin | -34.96% | -45.68% | -37.15% | -35.87% |
Earnings per share | -0.39 | -0.50 | -0.45 | -0.42 |
Interest and investment income | 7.39M | 10.03M | 11.15M | 10.20M |
Interest expense | -943.00K | -1.18M | -3.05M | -1.35M |
Net interest expenses | 6.45M | 8.85M | 8.10M | 8.85M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -89.47M | -110.64M | -111.91M | -118.56M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1